0.4948USD+30.90%Mkt Cap: 10.15M USDP/E: —Last update: 2026-05-26
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-a…
Industry Peers
Medical Devices151.38BUSDP/E 24.3
119.84BUSDP/E 36.2
86.12BUSDP/E 24.2
54.95BSEKP/E 101.9
53.92BSEKP/E 22.9
52.13BDKKP/E 22.1
50.54BUSDP/E 47.4
39.31BEURP/E 18.6
Indicators:|
Key Statistics
Company
Market Cap10.15M USD
Enterprise Value5.50M USD
Revenue (TTM)275.58K USD
Gross Profit240.27K USD
Net Income (TTM)-8.22M USD
Revenue/Share0.0150 USD
Last Price0.4948 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.29
PEG—
EV/EBITDA-0.65
EV/Revenue19.97
P/S31.19
P/B2.05
EPS (TTM)-0.46
EPS (Forward)-0.31
52W Range
0.305011% of range2.000
52W High2.000 USD
52W Low0.3050 USD
Profitability
Gross Margin79.65%
Oper. Margin-14179.95%
EBITDA Margin0.00%
Profit Margin-2725.76%
ROE-219.38%
ROA-177.38%
Growth
Revenue Growth-63.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.96M USD
CapEx (TTM)96.86K USD
FCF Margin-759.28%
FCF Yield-20.62%
Net Debt-2.71M USD
Net Debt/EBITDA0.32
Balance Sheet
Debt/Equity—
Current Ratio4.07
Quick Ratio3.40
Book Value/Sh0.1950 USD
Cash/Share0.1320 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.000 USD
Target Range2.000 USD – 2.000 USD
# Analysts1
Ownership
Shares Out.21.54M
Float17.86M
Insiders11.23%
Institutions5.18%
Short Interest
Short Ratio0.6d
Short % Float2.94%
Short % Out.2.78%
Shares Short573.19K
Short (prev mo.)481.97K
Technical
SMA 500.3870 (+27.9%)
SMA 2000.7576 (-34.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)879.88K
Avg Vol (10d)341.60K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—